Performance of laboratories in antimicrobial susceptibility testing of MB-16-08
| Antibiotics | MIC | Antibiotics | Disk | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | I | R | IND | S | I | R | IND | ||
| CLSI group A | |||||||||
| Ampicillin | 212 | Ampicillin | 21 | ||||||
| Penicillin G | 205 | Penicillin G | 19 | ||||||
| Other CLSI groups | |||||||||
| Chloramphenicol | 1 | Chloramphenicol | 2 | 2 | |||||
| Daptomycin | 49 | Erythromycin | 1 | 14 | |||||
| Erythromycin | 1 | 61 | Gentamicin-high | 4 | |||||
| Gentamicin-high | 148 | Linezolid | 4 | 1 | |||||
| Linezolid | 211 | 1 | Rifampin | 1 | |||||
| Quinupristin/Dalfopristin | 32 | Streptomycin-high | 3 | ||||||
| Rifampicin | 1 | 1 | Teicoplanin | 9 | |||||
| Rifampin | 1 | 3 | 11 | Vancomycin | 21 | 2 | |||
| Streptomycin-high | 144 | 1 | |||||||
| Teicoplanin | 57 | ||||||||
| Vancomycin | 215 | ||||||||
| Unacceptable | |||||||||
| Ciprofloxacin | 23 | Cefazolin | 2 | ||||||
| Clindamycin | 1 | 2 | Cefoperazone/Sulbactam | 1 | |||||
| Gentamicin | 1 | 1 | Cefotaxime | 1 | |||||
| Levofloxacin | 15 | Cefoxitin | 1 | ||||||
| Nitrofurantoin | 7 | Ceftazidime | 3 | ||||||
| Norfloxacin | 5 | Ceftriaxone | 3 | ||||||
| Oxacillin | 1 | Cephalothin | 2 | ||||||
| Streptomycin | 1 | Ciprofloxacin | 11 | ||||||
| Tetracycline | 24 | Clindamycin | 7 | ||||||
| Trimethoprim/Sulfamethoxa | 1 | 1 | Gentamicin | 2 | 1 | ||||
| Levofloxacin | 2 | ||||||||
| Netilmicin | 1 | ||||||||
| Oxacillin | 5 | ||||||||
| Tetracycline | 8 | 1 | |||||||
| Trimethoprim/Sulfamethoxa | 2 | ||||||||
| IND | |||||||||
| Ampicillin/Sulbactam | 6 | Amoxicillin/Clavulanic acid | 1 | ||||||
| Imipenem | 6 | Ampicillin/Sulbactam | 3 | ||||||
| Telithromycin | 1 | Imipenem | 2 | ||||||
| Tigecycline | 5 | Meropenem | 2 | ||||||
| Piperacillin/Tazobactam | 1 | ||||||||
Abbreviations: MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistance; IND, indeterminate; CLSI, Clinical and Laboratory Standards Institute.